Cargando…
Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
Autor principal: | Kawahara, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589384/ https://www.ncbi.nlm.nih.gov/pubmed/32770604 http://dx.doi.org/10.1111/iju.14346 |
Ejemplares similares
-
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018) -
Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022) -
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011) -
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022) -
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
por: Shao, Yu-Hsuan Joni, et al.
Publicado: (2022)